Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628937 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL13281880 | 0.91 | CYP3A4 (0.50) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL12151903 | 0.90 | CYP3A4 (0.41) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL12151888 | 0.90 | CYP3A4 (0.47) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL1732109 | 0.88 | CYP2C19 (0.48) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL14883414 | 0.88 | CYP3A4 (0.48) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL14883416 | 0.88 | CYP3A4 (0.46) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL12151997 | 0.88 | CYP3A4 (0.48) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL12151992 | 0.88 | CYP3A4 (0.48) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL12151896 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP2C19CYP2C9CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2696937-B1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-20130102615-A1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-25 | — | — | US | disclosed |
| EP-1943221-B1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7396830-B2 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| WO-2007041616-A1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102615-A1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | CD4, TAF15, ACIN1 | CYP3A4 187/4885CYP2C19 204/4885CYP2C9 220/4885 |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | IDO1, IDO2, EIF2AK2 | CYP3A4 644/4885CYP2C19 923/4885CYP2C9 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.